Trial Profile
Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs CAL 02 (Primary)
- Indications Community-acquired pneumonia
- Focus Adverse reactions; First in man
- Sponsors Combioxin
- 27 Mar 2018 Status changed from recruiting to completed.
- 23 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2018.
- 20 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.